Druck Icon

Eckert & Ziegler is awarded the Contract for Radiodiagnostics in Gdansk

Berlin, 21 June 2010. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for special preparations for the diagnosis and treatment of cancer has been awarded the tendered contract for the regular supplies of radiodiagnostics to the Polish Medical University of Gdansk via its subsidiary Eckert & Ziegler f-con Deutschland GmbH. The contract valued at approx. Euro 1.3 million relates to the diagnostic substance fluor deoxyglucose (FDG), which is used for the reliable and quick diagnosis of the smallest tumours via positron emission computer-assisted tomography (PET). Due to its short half-life time FDG must be locally manufactured daily using cyclotrons, enabling fresh supplies to the clinics. The Managing Director, Axel Schmidt, declared: "Our tender was convincing because of our track record in Poland where we have been supplying Polish specialists in nuclear medicine with reliable deliveries of FDG for many years. Our intention, in addition to our market leadership in Germany and Poland, is to continue extending our manufacturing network and consolidating it with further production locations."

Eckert & Ziegler already has several radiopharmaceutical manufacturing locations in Germany and also markets, in addition to Fluor 18-based radiodiagnostics for nuclear medical imaging (PET), the licensed product Yttriga, a precursor of many radio therapeutics. In addition Eckert & Ziegler supplies nuclear medical facilities with synthesis technology.

About Eckert & Ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG is a global isotope technology company and holding company for a number of specialized subsidiary companies in the field of processing of radioisotopes and of development, production, and marketing of isotope technology components, medical devices, and similar products. The quoted group generated a turnover of EUR 101 million in 2009 and is one of the largest suppliers of radioactive components for radiation therapy and nuclear medicine, employing 520 employees worldwide. Please visit our website at www.ezag.com for more information on Eckert & Ziegler.

The Board of Directors